RESEARCH HIGHLIGHT 25 January 2024 In patients with resected, high-risk melanoma, the addition of a personalized mRNA-based neoantigen therapy to adjuvant pembrolizumab was more effective than pembrolizumab alone. Karen O’Leary Karen O’Leary is an Associate Research Analysis Editor with Nature Medicine. Adjuvant checkpoint inhibitor therapy is the standard of care for resectable melanoma. Although many patients derive lasting benefit from the treatment, a substantial number experience disease re...